AUTH/2798/10/15 - Director of Pharmacy v Grunenthal

Conduct of a representative

  • Received
    06 October 2015
  • Case number
    AUTH/2798/10/15
  • Applicable Code year
    2015
  • Completed
    16 November 2015
  • No breach Clause(s)
    8.2, 9.1, 11.1, 11.2, 15.2 and 15.9
  • Additional sanctions
  • Appeal
    No appeal
  • Review
    February 2016

Case Summary

A director of pharmacy complained about the conduct of a representative from Grunenthal. The representative had promoted Palexia (tapentadol) and Versatis (lidocaine). Palexia was indicated for the relief of moderate to severe acute pain in adults, which could be adequately managed only with opioid analgesics. Versatis was indicated in adults for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection. 

The complainant alleged a significant amount of promotional material for Palexia and Versatis had been left on one of the care of the elderly wards in his hospital with the intention of promoting to staff, patients and carers. The complainant provided some of the material retrieved by one of the pharmacists from the ward. 

The complainant further alleged that the representative had stated that the pharmacy department actively sought to curtail consultants' freedom to prescribe Grunenthal products; this despite the presence of both Palexia and Versatis on the local formulary. 

The complainant alleged that in his view the behaviours exhibited breached the Code. 

The detailed response from Grunenthal is given below. 

The Panel noted that the Grunenthal representative conducted a promotional meeting with ward staff, the meeting being held in a room at the closed end of a short corridor which was remote from, and to one side of, the bed area. Grunenthal stated that the room was for the use of clinical staff only. In the Panel's view, given the ward layout, it was unlikely that carers or patients would have used the corridor or entered the staff room. The Panel noted that the representative took material to the meeting for 12 attendees; only 8 turned up and one took some of the leftover material for a colleague. The representative left the remaining material in the staff room. 

The Panel noted that the complainant had alleged that the material had been found 'on the ward' by a colleague; he had not described where on the ward the material had been found. The Panel noted that even if some of the material had been found in an area accessible by patients or carers the complainant had provided no information to prove that, on the balance of probabilities, it had been left there by the representative – it could have inadvertently been put down by one of the attendees. Once leavepieces and the like were given to staff, representatives had no control of what happened to them.

The Panel considered that the complainant had not established, on the balance of probabilities, that the representative had left promotional material on a part of the ward accessible to patients and carers. The material had been distributed to those categories of persons whose need for or interest in it could be reasonably assumed. No breach of the Code was ruled. 

With regard to the spare material which was left by the representative, the Panel considered that although it might be good practice to have removed the material at the end of a meeting, whether it was acceptable to do otherwise would depend on a number of factors such as the location and general use of the area in which the material was left and the amount which was left. In the Panel's view, it was not unreasonable, in the context of a pre-planned meeting, to leave promotional material for those who had been expected to attend but were absent on the day. The material had been left in a room used by clinical staff following a promotional meeting with health professionals. In any event, the Panel noted its comments above about a representative having no way of controlling what health professionals did with material after a meeting was finished. On balance, the Panel ruled no breach of the Code.

The Panel noted that the briefing material for the Versatis and the Palexia leavepieces clearly informed representatives that the materials were promotional items for health professionals which should not be left with receptionists or secretaries unless specifically requested to do so, in writing, by a health professional. The Palexia briefing stated that the item 'should only be left with [health professionals] following a promotional call'. The Versatis leavepiece briefing clearly stated that the leavepiece was not to be left with or shown to patients. In the Panel's view none of the briefing material advocated either directly or indirectly that the leavepieces should be used with patients or carers in a way which would be likely to breach the Code. No breach of the Code was ruled. 

The Panel noted the complainant's allegation that the representative had stated that the pharmacy department was actively trying to curtail prescribing of Grunenthal's medicines despite the fact that both Palexia and Versatis were on the formulary. The Panel noted Grunenthal's submission regarding what appeared to be confusion about the prescribing of Palexia to in-patients and that it could only be prescribed if a form, ordinarily used for the assessment and approval of high cost medicines, was completed and submitted. In the Panel's view, given Grunenthal's account of the apparent confusion about how Palexia could be prescribed, it was not unreasonable for the representative to try to find out what the situation was. Grunenthal had submitted that some health professionals in the hospital had expressed frustration about the matter. Overall, the Panel did not consider that it had any information before it to show that in trying to establish the facts, the representative had disparaged the opinions of any health professional. No breach of the Code was ruled.

The Panel noted its rulings above and did not consider that the representative had failed to maintain a high standard of ethical conduct. No breaches of the Code were ruled.​​